pioglitazone has been researched along with Cerebellar Diseases in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Cerebellar Diseases: Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysmetria, GAIT ATAXIA, and MUSCLE HYPOTONIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toba, J | 1 |
| Nikkuni, M | 1 |
| Ishizeki, M | 1 |
| Yoshii, A | 1 |
| Watamura, N | 1 |
| Inoue, T | 1 |
| Ohshima, T | 1 |
1 other study available for pioglitazone and Cerebellar Diseases
| Article | Year |
|---|---|
PPARγ agonist pioglitazone improves cerebellar dysfunction at pre-Aβ deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebellar Diseases; Intercellular Signaling Pept | 2016 |